Laliberte Kevin
Sr. VP, Product Development at Dova Pharmaceuticals Inc.
- Sold, on record
- $205k
- Dollars the filings state
- Form 4 sales
- 4
- Latest Sep 30, 2019
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- Dova Pharmaceuticals Inc.Sr. VP, Product Development
Sales by reason
0
Routine
0
Plan not stated
0
No plan
0
Unusual
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale Dova Pharmaceuticals Inc.Plan not statedJul 1 2019
Sold 1,191 shares at $14.17 ($17k)
Laliberte Kevin, Sr. VP, Product Development
Sold 8.4% of holdings ($200k position)12,946 shares leftFirst sale on recordFiling
- 2 Form 4 sale Dova Pharmaceuticals Inc.Plan not statedJul 31 +30 days
Sold 1,389 shares at $15.97 ($22k)
Laliberte Kevin, Sr. VP, Product Development
Sold 10.7% of holdings ($207k position)11,557 shares leftFiling
- 3 Form 4 sale Dova Pharmaceuticals Inc.UnusualSep 25 +56 days
Sold 3,100 shares at $20.00 ($62k)
Laliberte Kevin, Sr. VP, Product Development
Sold 26.8% of holdings ($231k position)8,457 shares leftFiling
- 4 Form 4 sale Dova Pharmaceuticals Inc.UnusualSep 30 +5 days
Sold 3,696 shares at $28.00 ($103k)
Laliberte Kevin, Sr. VP, Product Development
Sold 43.7% of holdings ($237k position)4,761 shares left2.7x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (4)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2019 | Dova Pharmaceuticals Inc. | Sr. VP, Product Development | Form 4 sale | 3,696 | $103k | 43.7% | Unusual | SEC |
| Sep 25, 2019 | Dova Pharmaceuticals Inc. | Sr. VP, Product Development | Form 4 sale | 3,100 | $62k | 26.8% | Unusual | SEC |
| Jul 31, 2019 | Dova Pharmaceuticals Inc. | Sr. VP, Product Development | Form 4 sale | 1,389 | $22k | 10.7% | Plan not stated | SEC |
| Jul 1, 2019 | Dova Pharmaceuticals Inc. | Sr. VP, Product Development | Form 4 sale | 1,191 | $17k | 8.4% | Plan not stated | SEC |